" Application of Art Therapy in Oncology: Evaluation of the Symptomatic of Patients Suffering From a Cancerous Disease" — ARONCO  

Therapy-Associated Cancer Clinical Trial

Official title: " Application of Art Therapy in Oncology: Evaluation of the Symptomatic of Patients Suffering From a Cancerous Disease"

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the impact of art-therapeutic management on a patient with cancer, during chemotherapy treatment, on the reduction of physical or psychological symptoms.

Art therapy is a non-drug approach that can help some patients cope with the consequences of cancer beyond the care provided.

The common psychosocial difficulties experienced by cancer patients are pain, fatigue, depression, anxiety, drowsiness. In sum, the well-being and quality of life of the patient throughout the illness.

The main objective is to evaluate the impact of art therapy, as a supportive care, on improving the well-being felt after a session of cancer treatments (chemotherapy, immunotherapy, ...), during 6 sessions( around 24 days between 2 sessions) , at patients with a cancer pathology using two questionnaires, one on the evaluation of symptoms (ESAS), the other on the quality of life (FACT-G).

Clinical Trial Description

Patients will be randomized into the following groups:

• Group 1: Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care

• Group 2: 6 consecutive sessions of cancer treatments with or without additional supportive care.

Symptom assessment with the Edmonton Symptom Assessment System (ESAS) is done before and after each treatment session for each patient.

The FACT-G questionnaire on the quality of life at the beginning and the end of the care for the two groups (group benefiting from the art-therapy and group not benefiting from the art-therapy) and a questionnaire on the contribution of art therapy, at the end of care, for the participants of the art-therapy group. ;

Related Conditions & MeSH terms

• Neoplasms, Second Primary
• Therapy-Associated Cancer

• NCT number: NCT04195217
• Study type: Interventional
• Source: Centre Hospitalier de Perigueux
• Contact: Sébastien SB BOUTREUX, Doctor
• Phone: (+33)5.53.45.25.25
• Email: sebastien.boutreux@ch-perigueux.fr
• Status: Recruiting
• Phase: N/A
• Start date: January 7, 2020
• Completion date: December 31, 2023